CNBC: 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
On , Novo Nordisk announced it had launched an oral tablet version of its injectable GLP-1 weight-loss medication, Wegovy (semaglutide). The GLP-1 pill is still prescription-only, but ...
The FDA just approved the first pill version of a blockbuster GLP-1 drug for weight loss, a move that could significantly widen access to the treatment, though the full costs aren’t clear. The ...
GLP-1 weight-loss pills appear to be just as effective as injections, with clinical trials showing similar average weight loss when taken correctly. The safety profile of GLP-1 pills largely mirrors ...
CNBC on MSN: Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
The Washington Post: Wegovy pill could deliver as much weight loss as the shot, trial shows
Novo Nordisk said that patients taking a pill form of Wegovy in a clinical trial lost about as much weight as those who get the shot version, fueling new optimism that oral GLP-1 drugs could expand an ...